Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.

Transcription

1 Index Note: Page numbers of article titles are in boldface type. A AADs. See Antiarrhythmic drugs (AADs) ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors ACP in transseptal approach to AF, AF. See Atrial fibrillation (AF) AFP. See Anterior fat pad (AFP) Aging AF due to, Aldosterone antagonists, 543 Amiodarone rhythm control related, 537 Angiotensin-converting enzyme (ACE) inhibitors, 542 Angiotensin receptor blockers (ARBs), 542 Anterior fat pad (AFP) preservation Anti-inflammatory agents, 543 Antiarrhythmic drugs (AADs) in AF follow-up care, , inpatient vs. outpatient initiation, 539 introduction, rhythm control related, amiodarone, 537 decision in, 535 disopyramide, 535 dofetilide, dronedarone, flecainide and propafenone, ibutilide, 538 pharmacologic cardioversion, quinidine, 535 rules in selection, sotalol, 536 vs. rate control, 534 vs. catheter ablation, Anticoagulant(s), vitamin K antagonists, Anticoagulation in AF follow-up care, 512 Cardiol Clin 32 (2014) /14/$ see front matter Ó 2014 Elsevier Inc. All rights reserved. in catheter ablation, 552 Antiplatelet agents in patients undergoing percutaneous coronary interventions/stenting, Antithrombotic agents, ARBs. See Angiotensin receptor blockers (ARBs) Atrial dilatation and stretch AF related to, 488 Atrial fibrillation (AF) classification of, 534 diagnostic evaluation of, clinical history in, medications, 511 past medical history, quality of life, symptoms, introduction, 507 physical examination in, epidemic of, follow-up care, antiarrhythmic therapy in, anticoagulation in, 512 RFA in, 515 genetics in, variants, common, ion channel genes, non ion channel genes, 490 rate, incidence of, 533 introduction, 485, 573, maintenance of high DF sites and, management of AADs in, See also Antiarrhythmic drugs (AADs), ACE inhibitors in, 542 aldosterone antagonists in, 543 anticoagulants in, introduction, antiinflammatory agents in, 543 antiplatelet agents in patients undergoing percutaneous coronary interventions/ stenting in, antithrombotic therapy in, introduction, ARBs in, 542 cardiology.theclinics.com

2 652 Index Atrial (continued ) AVJ ablation in, See also Atrioventricular junction (AVJ) ablation, in AF management cardiac resynchronization therapy in catheter ablation in, See also Catheter ablation, as first-line treatment, vs. AADs, future directions in, hydroxy-3-methylglutaryl coenzyme A reductase inhibitors/statins in, LAA exclusion in, See also Left atrial appendage (LAA) exclusion, for AF ranolazine in, 544 rate control in, vs. rhythm control, described, drug therapy in sinus rhythm maintenance, surgery in, Cox-Maze procedure, See also Cox-Maze procedure, in surgical management of AF indications for, 564 introduction, upstream, vernakalant in, 544 mechanisms of, frequency-dependent breakdown of wave propagation, introduction, transition from paroxysmal to PeAF reflected by DF changes, translation to patients, perpetuation of inflammation in, prevention of, sustained high-frequency atrial excitation results in oxidative stress in, persistent. See Persistent atrial fibrillation (PeAF) new animal model of, postoperative, See also Postoperative atrial fibrillation (POAF) prevalence of, 485, 507, 533 prevention of outlook for, 646 remodeling of Gal-3 in, risk factors for, aging, atrial dilatation and stretch, 488 CAD, hypertension, 486 pericardial fat and obesity, 487 sleep apnea, stroke related to bleeding risk and, mechanisms of, tachycardia-induced cardiomyopathy related to, Atrial fibrosis RAAS and, Atrial pacing prophylactic 631 Atrioventricular junction (AVJ) ablation, alternatives to, complications of, device selection after, hemodynamics of, 576 indications for, 574 long-term outcomes after, 579 new technology for, procedure, tachycardia-induced cardiomyopathy related to, B b-blockers in POAF management, C CAD. See Coronary artery disease (CAD) Calcium channel blockers Cardiac resynchronization therapy AF and Cardiomyopathy tachycardia-induced AF and, Catheter ablation, anticogulation in, 552 as first-line treatment, introduction, 551 outcomes of, complications-related, 558 mortality benefits, 558 procedural success, stroke benefit, patient selection for, 551 postprocedure care and follow-up, preoperative planning for, preprocedure testing for, strategies for, AF mechanisms, 552 cryoballoon catheter, 554 PVI, vs. AADs,

3 Index 653 Coronary artery disease (CAD) heart failure and, Cox-Maze procedure in surgical management of AF, patient positioning in, 564 perioperative and postoperative management in, 568 preoperative planning in, 564 results of, technique, right mini-thoractomy approach, sternotomy approach, Cryoballoon catheter in catheter ablation, 554 D DF. See Dominant frequency (DF) Digoxin Disopyramide rhythm control related, 535 Dofetilide rhythm control related, Dominant frequency (DF) changes in transition from paroxysmal to PeAF reflected by, high AF maintenance related to, Dronedarone rhythm control related, Drug therapy. See also specific types in sinus rhythm maintenance, E Electrical cardioversion F Flecainide and propafenone rhythm control related, G Gal-3 in AF remodeling, H Heart failure CAD and, Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors/statins, Hypertension AF due to, 486 I Ibutilide rhythm control related, 538 dofetilide and Inflammation AF perpetuation related to, L LAA. See Left atrial appendage (LAA) Left atrial appendage (LAA) dysfunction of stroke and, function of, 604 morphologic variation of, morphology and microstructure complexity of, 606 morphology of, regional anatomy of, 603 structure of, Left atrial appendage (LAA) closure in cardioembolic risk reduction, surgical approaches, minimally invasive approach, 607 percutaneous, 607 Left atrial appendage (LAA) exclusion for AF, complications of prevention/management of, epicardial approach, 612 hybrid approach, introduction, 601 transseptal approach, ACP, PLAATO system, 607 WATCHMAN, WaveCrest system, 611 unanswered questions related to, M Magnesium Myopathy stroke and, N Non vitamin K antagonist oral anticoagulants,

4 654 Index O Obesity AF related to, 487 Oxidative stress sustained high-frequency atrial excitation resulting in, P Paroxysmal atrial fibrillation (AF) to PeAF DF changes related to, PeAF. See Persistent atrial fibrillation (PeAF) Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO) system in transseptal approach to AF, 607 Pericardial fat AF related to, 487 Pericardiotomy posterior Persistent atrial fibrillation (PeAF) transition from paroxysmal to DF changes related to, Pharmacologic cardioversion in rhythm control, PLAATO system. See Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO) system POAF. See Postoperative atrial fibrillation (POAF) Posterior pericardiotomy Postoperative atrial fibrillation (POAF), epidemiology of, introduction, 627 management of AADs in, 630 AFP preservation in, 631 amiodarone in, 630 anticoagulation in, 631 b-blockers in, calcium channel blockers and digoxin in, 630 electrical cardioversion in, 631 goals in, 629 ibutilide and dofetilide in, 630 magnesium in, 630 nonpharmacologic strategies in, pharmacologic agents in, posterior pericardiotomy in, 631 prophylactic atrial pacing in, sotalol in, 630 mechanism of, prognosis of, 629 recurrence of, 632 Propafenone and flecainide rhythm control related, Prophylactic atrial pacing 631 Pulmonary vein isolation (PVI) in catheter ablation, PVI. See Pulmonary vein isolation (PVI) Q Quality of life in AF evaluation, Quinidine rhythm control related, 535 R RAAS. See Renin-angiotensin-aldosterone system (RAAS) Radiofrequency ablation (RFA) in AF follow-up care, 515 Ranolazine, 544 Refractory AF/atrial flutter and rapid ventricular rates Renin-angiotensin-aldosterone system (RAAS) atrial fibrosis and, RFA. See Radiofrequency ablation (RFA) S Sinus rhythm in AF maintenance of drug therapy in, Sleep apnea AF related to, Sotalol rhythm control related, 536 Stroke AF and bleeding risk associated with, mechanisms of, LAA dysfunction related to, myopathy and, nonpharmacologic prevention of, risk factors for prevention of catheter ablation in, T Tachycardia-induced cardiomyopathy AF and,

5 Index 655 Thromboembolism prevention of, V Vernakalant, 544 Vitamin K antagonists, W WATCHMAN in transseptal approach to AF, Wave propagation frequency-dependent breakdown of in AF, WaveCrest system in transseptal approach to AF, 611